ijms-logo

Journal Browser

Journal Browser

Molecular Advances in Helicobacter pylori Infections and Treatments

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Microbiology".

Deadline for manuscript submissions: closed (31 January 2024) | Viewed by 2704

Special Issue Editor


E-Mail Website
Guest Editor
1. Head of the Department of Pancreatic, Biliary and Upper Digestive Tract Disorders, A. S. Loginov Moscow Clinical Scientific Centre, 101000 Moscow, Russia
2. Professor of the Department of Outpatient Therapy and Family Medicine, Tver State Medical University, 101000 Tver, Russia
3. Professor of the Department of Propaedeutic of Internal Diseases and Gastroenterology A.I. Yevdokimov Moscow State University of Medicine and Dentistry, 101000 Moscow, Russia
Interests: acid-related disorders; H. pylori-associated diseases; GERD; diagnosis and treatment of diseases of the upper digestive tract; pancreas and biliary system

Special Issue Information

Dear Colleagues,

I am pleased to invite you to submit research articles to the upcoming Special Issue of IJMS, entitled “Molecular Advances in Helicobacter pylori Infections and Treatments”.

The range of H. pylori-associated diseases is wide and is determined by the interaction of three main factors: the microbe, host organism, and the environment.

The aims of this issue includes the development and implementation of highly valid diagnostic tests for H. pylori infection, molecular genetic research into the infect’s properties, study of the clue mechanisms of bacterial pathogenesis, modulation of stomach microbiota, prognostic factors of outcomes, progress in the treatment of Helicobacter pylori-associated diseases, and assessment the gastric mucosa repair after eradication. This is a far from exhaustive account of the questions under active consideration by scientists and clinicians in the world. The Maastricht VI/Florence Consensus Report was published in 2022 and outlined research challenges for the next five years: the mission of the global prevention of gastric cancer; a need better to understand and control antibiotic resistance, which continues to grow dramatically; the aim to improve potential treatments/combinations, including achieving optimal supression of acidity.

In this context, it is extremely important to accumulate innovative ideas and experience, to study regional peculiarities and to combine efforts in solving global research tasks.

This Special Issue will focus on the latest advances in innovative diagnostics and treatments for H. pylori.

Topics of interest include, but are not limited to, the following:

  • Molecular advances of the diseases when encountered in the pathogen of H. pylori;
  • New strategies against H. pylori biofilm formation;
  • New synergic natural compounds/antibiotic association in H. pylori treatment;
  • Epidemiological aspects of H. pylori infection and diseases associated with H. pylori;
  • Mechanisms of development of H. pylori-associated diseases;
  • The course of diseases after H. pylori eradication therapy;
  • H. pylori prevention.

Prof. Dr. Dmitry Bordin
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • H. pylori
  • gastritis
  • carcinogenesis
  • mechanisms of pathogenicity
  • molecular pathology
  • molecular genetics
  • microbiome modulation
  • antibiotic resistance
  • eradication
 

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

11 pages, 619 KiB  
Article
Helicobacter pylori and Pro-Inflammatory Protein Biomarkers in Myocardial Infarction with and without Obstructive Coronary Artery Disease
by Jonatan Wärme, Martin O. Sundqvist, Marcus Hjort, Stefan Agewall, Olov Collste, Christina Ekenbäck, Mats Frick, Loghman Henareh, Claes Hofman-Bang, Jonas Spaak, Peder Sörensson, Shams Y-Hassan, Per Svensson, Bertil Lindahl, Robin Hofmann and Per Tornvall
Int. J. Mol. Sci. 2023, 24(18), 14143; https://doi.org/10.3390/ijms241814143 - 15 Sep 2023
Viewed by 921
Abstract
Myocardial infarction (MI) with obstructive coronary artery disease (MI-CAD) and MI in the absence of obstructive coronary artery disease (MINOCA) affect different populations and may have separate pathophysiological mechanisms, with greater inflammatory activity in MINOCA compared to MI-CAD. Helicobacter pylori (Hp) can cause [...] Read more.
Myocardial infarction (MI) with obstructive coronary artery disease (MI-CAD) and MI in the absence of obstructive coronary artery disease (MINOCA) affect different populations and may have separate pathophysiological mechanisms, with greater inflammatory activity in MINOCA compared to MI-CAD. Helicobacter pylori (Hp) can cause systemic inflammation and has been associated with cardiovascular disease (CVD). We aimed to investigate whether Hp infection is associated with concentrations of protein biomarkers of inflammation and CVD. In a case-control study, patients with MINOCA (n = 99) in Sweden were included, complemented by matched subjects with MI-CAD (n = 99) and controls (n = 100). Protein biomarkers were measured with a proximity extension assay in plasma samples collected 3 months after MI. The seroprevalence of Hp and cytotoxin-associated gene A (CagA) was determined using ELISA. The associations between protein levels and Hp status were studied with linear regression. The prevalence of Hp was 20.2%, 19.2%, and 16.0% for MINOCA, MI-CAD, and controls, respectively (p = 0.73). Seven proteins were associated with Hp in an adjusted model: tissue plasminogen activator (tPA), interleukin-6 (IL-6), myeloperoxidase (MPO), TNF-related activation-induced cytokine (TRANCE), pappalysin-1 (PAPPA), soluble urokinase plasminogen activator receptor (suPAR), and P-selectin glycoprotein ligand 1 (PSGL-1). Hp infection was present in one in five patients with MI, irrespective of the presence of obstructive CAD. Inflammatory proteins were elevated in Hp-positive subjects, thus not ruling out that Hp may promote an inflammatory response and potentially contribute to the development of CVD. Full article
(This article belongs to the Special Issue Molecular Advances in Helicobacter pylori Infections and Treatments)
Show Figures

Figure 1

14 pages, 6881 KiB  
Article
Dimethylaminododecyl Methacrylate-Incorporated Dental Materials Could Be the First Line of Defense against Helicobacter pylori
by Xi Chen, Tiantian Shan, Biao Ren, Lin Zhang, Hockin H. K. Xu, Nanxi Wang, Xuedong Zhou, Hong Li and Lei Cheng
Int. J. Mol. Sci. 2023, 24(17), 13644; https://doi.org/10.3390/ijms241713644 - 04 Sep 2023
Cited by 1 | Viewed by 1157
Abstract
Oral cavity is an essential reservoir for H. pylori. We aimed to investigate the antibacterial effects of dimethylaminododecyl methacrylate (DMADDM) against H. pylori. Modified giomers were prepared by introducing 0%, 1.25% and 2.5% DMADDM monomers. Broth microdilution assay, spot assay, Alamer [...] Read more.
Oral cavity is an essential reservoir for H. pylori. We aimed to investigate the antibacterial effects of dimethylaminododecyl methacrylate (DMADDM) against H. pylori. Modified giomers were prepared by introducing 0%, 1.25% and 2.5% DMADDM monomers. Broth microdilution assay, spot assay, Alamer Blue assay, PMA–qPCR, crystal violet staining, scanning electron microscopy observation and live/dead bacterial staining were performed to evaluate the antibacterial and antibiofilm effects of DMADDM and modified giomers in vitro. Urease assay, qPCR, hematoxylin–eosin staining and ELISA were performed to evaluate the inflammation levels and colonization of H. pylori in vivo. In vitro experiments indicated that the minimum inhibitory concentration and minimum bactericidal concentration of DMADDM were 6.25 μg/mL and 25 μg/mL, respectively. It inhibited H. pylori in a dose- and time-dependent manner, and significantly reduced the expression of cagA, vacA, flaA and ureB. DMADDM-modified giomers inhibited the formation of H. pylori biofilm and reduced live cells within it. In vivo experiments confirmed that the pretreatment with DMADDM-modified dental resin effectively reduced the gastric colonization of oral–derived H. pylori, suppressed systemic and local gastric inflammation. DMADDM monomers and DMADDM-modified giomers possessed excellent antibacterial and antibiofilm effects on H. pylori. Pretreatment with DMADDM-modified giomers significantly inhibited the gastric infection by H. pylori. Full article
(This article belongs to the Special Issue Molecular Advances in Helicobacter pylori Infections and Treatments)
Show Figures

Figure 1

Back to TopTop